Impaired adipogenesis plays an important role in the development of obesity-associated insulin
resistance and type 2 diabetes as it leads to ectopic fat deposition.
The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets
responsible for the impairment of adipogenesis. The expression of GATA-3 is higher in insulinresistant
obese individuals compared to BMI-matched insulin-sensitive counterparts. Adipose tissue inflammation
is a crucial mediator of this process.
Hyperglycemia mediates the activation of the immune system, partially through upregulation of GATA-
3, causing exacerbation of the inflammatory state associated with obesity.
This review discusses the evidence supporting the inhibition of GATA-3 as a useful therapeutic strategy
in obesity-associated insulin resistance and type 2 diabetes, through up-regulation adipogenesis and
amelioration of the immune response.